this is really the issue! when u have such effective systemic therapy options our approach to locally advanced NSCLC should evolve.. provocative Q.. do we really need chemoRT? should we rethink our approach? more local consolidate approaches (ablative/surgical) post ‘effective’

Interesting point! However consider this: if tumor volume is indeed critical factor utilizing chemo plus osi to achieve systemic control followed by local consolidative approaches like ablation or surgery could be more effective. This directly targets residual tumor burden

New from the #ASCO24 Plenary Session: LAURA shows osimertinib significantly improves PFS over placebo (39.1 vs 5.6 months) in pts w/ unresectable stage III EGFR-mutant #NSCLC following CRT: brnw.ch/21wKmUr #ASCODailyNews #LCSM Suresh S. Ramalingam, MD, FASCO Vamsi Velcheti, MD MBA FASCO

Great insights Julien Mazieres ADAURA & LAURA control arms indeed highlight this complexity suggesting what we perceive as localized might is more advanced at molecular level. i think there is a need for early n aggressive targeted therapies irrespective of clinical staging;

Host Stephen V Liu, MD moderates a discussion of lung cancer screening using low dose CT scans, which have been shown to detect #lungcancer earlier & significantly improve lung cancer mortality. W/guests Dr. Pan-Chyr Yang, & Elaine Shum. Listen: bit.ly/LCScreeningLCC #LCSM

Jill Feldman We hear you loud and clear. Hoping trials like this (c/o Stand Up To Cancer ) will help reduce treatment delays and discontinuation for patients, improving outcomes classic.clinicaltrials.gov/ct2/show/NCT05… Vamsi Velcheti, MD MBA FASCO Apricity Health @DrSteveMartin

It’s really demoralizing that a guy who has become the richest person in the world due to advances in science would attack one of the most respected scientists of our generation in a blatantly personal way. This makes me question whether it’s possible to stay here and expect

lol ! Kaushal Parikh 3 NTRK inhibitors but no NTRK patients—an intriguing paradox in precision medicine. It illustrates the complex interplay bw scientific advancement and practical realities of patient care

Podcast: ASCO24: Transforming the Lung Cancer Treatment Landscape dailynews.ascopubs.org/do/podcast-asc…

Interesting convo betw NYU's dir of thoracic medical oncology Vamsi Velcheti, MD MBA FASCO & Cleveland Clinic's Vice Chair Clin Research & thoracic oncologist Nathan A. Pennell MD, PhD, FASCO sharing thoughts on what's potentially practice changing from recent lung cancer trials data & abstracts at ASCO '24 meeting

🎙️ “It was a huge year for lung cancer [at #ASCO24].” Listen to key lung cancer takeaways from Vamsi Velcheti, MD MBA FASCO of @NYULangone and Nathan A. Pennell MD, PhD, FASCO of Cleveland Clinic on the #ASCODailyNews Podcast: brnw.ch/21wL0jL

Honored & humbled to be designated as a Fellow ASCO. Grateful for opportunities over the past decade to develop as an investigator, physician, advocate, mentor, and educator. Many thanks to Conquer Cancer, the ASCO Foundation and ASCO for all the support over the years. Looking forward to

.Elon Musk I did listen to the climate part and yeah, I do think it was dumb. I don't expect Donald J. Trump to know the nuances of various CO2 ppm levels and their consequences, and him reaching out to the person who has arguably done more for climate than anyone else is pretty

deeply saddened by the loss for our Perlmutter Cancer Center at NYU Langone Health NYU Grossman School of Medicine and the global oncology community. Dr. Jeff Weber was a dedicated colleague, friend, and mentor, passionately committed to building careers and fostering growth in others. He will be truly missed by all

🔥🚨Hot off the press. U.S. FDA approved #Lazertinib plus #Amivantamab for 1st line treatment of advanced non-small cell #LungCancer with #EGFR mutations (exon 19 or 21 L858R). Approval based on results of #MARIPOSA study ✅#mPFS: 23.7 months vs 16.6 months (for Osimertinib).

🚨FDA Approves New First-Line option Amivantamab Plus Lazertinib for EGFR+ Advanced NSCLC based on 🦋 #MARIPOSA trial ⬆️ PFS (23.3 vs 16.6 mos) HR 0.70 Compared to osimertinib 🟰Similar ORR (86% vs 85%) ⬆️ side effects that require close mgmt- drug rash, leg edema, IRR, VTE

Updated materials for download/order for AJCC v9 Staging for Thoracic Malignancies. Great resources I keep saved on my phone and in my white coat pocket ⁦IASLC⁩ iaslc.org/research-educa…

Nice to see but with a 5.6 mPFS in the control arm you begin to wonder if subjecting these patients to chemoRT is really the best approach; IMO patients with EGFR stage 3 perhaps need a more aggressive local consolidation approach following EGFR directed therapy! cannt wait to